Clinical Trial

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the efficacy and safety of Tislelizumab with Fruquintinib, Metronidazole treatment in MSS/MSI-L advanced colorectal cancer patients with high abundance of Fusobacterium nucleatum in a single arm Phase II clinical.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-09.
Status change: Recruiting → Active, Not Recruiting 2026-02-22
Trial Details
NCT Number NCT06356597
Lead Sponsor Jing-yuan Fang, MD, Ph. D
Conditions Colorectal Cancer
Enrollment 33 participants
Start Date 2024-04-19
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-12-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-24